Share Prices & Company Research

Market News

08 Mar 2021 | 13:11

Bavarian Nordic posts positive pre-clinical trial data for Covid-19 vaccine

(Sharecast News) - Shares in Bavarian Nordic surged at the start following the release of positive pre-clinical trial data for its Covid-19 vaccine candidate, ABNCoV2. The Danish biotechnology outfit said follow-up data from the study on its capsid virus like particle vaccine had confirmed that it induced neutralising antibodies against SARS-CoV-2, the virus responsible for Covid-19.

Indeed, the two high dose regimen without adjuvant, or boosters, triggered a greater than 50-fold increase in antibody levels in comparison to convalescent human samples.

Furthermore, when "challenged" with SARS-Cov-2, virus load was significantly reduced in all vaccinated groups and "no virus could be detected at any timepoint in the majority of the subjects vaccinated with two high doses of ABNCoV2."

As of 1446 GMT, shares of Bavarian Nordic were trading up by 7.43% to DKK217, having earlier in the session come within a whisker of its more than three-year highs of DKK261.0, after surging to DKK247.

Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.